Abstract
Background and Aims: Our previous yeast two-hybrid screening data showed the Fibrinogen alpha chain (FGA) as one of the candidate binding proteins of S regional of the HBsAg (HBs). In this study, we aimed to define that FGA is a binding protein of HBs and to determine its function in Hepatocellular carcinoma (HCC) tumorigenesis.
Methods: The binding and co-localization between HBs and FGA were confirmed using co-immunoprecipitation and confocal microscopy was employed flow cytometry to analyze cell apoptosis. The involved mechanisms were investigated using protein array and western blot.
Results: Our results indicated that FGA is a binding protein of HBs and is co-localized in the cytoplasm in vitro. Interaction between HBs and FGA significantly induced apoptosis in HepG2 cells. Moreover, knockdown of the FGA protein decreased the expression levels of the pro-survival factors Bcl-XL and Mcl-1, increased the expression of the proapoptotic proteins, and decreased the phosphorylation levels of Akt in this cell.
Conclusion: FGA is a binding protein of HBs and their interaction induced the apoptotic capacity of HepG2 cells, suggesting the interactions between viral and host cell proteins are involved in the development of virus-related hepatitis or HCC.
Keywords: Binding protein, FGA, HBs, HepG2 cell apoptosis.
Current Proteomics
Title:Fibrinogen Alpha Chain Acts as a HBsAg Binding Protein and their Interaction Promotes HepG2 Cell Apoptosis
Volume: 11 Issue: 1
Author(s): Ping Li, Li Xiao, Ying-Ying Li, Xu Chen, Chuan-Xing Xiao, Jing-Jing Liu, Xiao-Ning Yang, Amarsanaa Jazag, Jian-Lin Ren and Bayasi Guleng
Affiliation:
Keywords: Binding protein, FGA, HBs, HepG2 cell apoptosis.
Abstract: Background and Aims: Our previous yeast two-hybrid screening data showed the Fibrinogen alpha chain (FGA) as one of the candidate binding proteins of S regional of the HBsAg (HBs). In this study, we aimed to define that FGA is a binding protein of HBs and to determine its function in Hepatocellular carcinoma (HCC) tumorigenesis.
Methods: The binding and co-localization between HBs and FGA were confirmed using co-immunoprecipitation and confocal microscopy was employed flow cytometry to analyze cell apoptosis. The involved mechanisms were investigated using protein array and western blot.
Results: Our results indicated that FGA is a binding protein of HBs and is co-localized in the cytoplasm in vitro. Interaction between HBs and FGA significantly induced apoptosis in HepG2 cells. Moreover, knockdown of the FGA protein decreased the expression levels of the pro-survival factors Bcl-XL and Mcl-1, increased the expression of the proapoptotic proteins, and decreased the phosphorylation levels of Akt in this cell.
Conclusion: FGA is a binding protein of HBs and their interaction induced the apoptotic capacity of HepG2 cells, suggesting the interactions between viral and host cell proteins are involved in the development of virus-related hepatitis or HCC.
Export Options
About this article
Cite this article as:
Li Ping, Xiao Li, Li Ying-Ying, Chen Xu, Xiao Chuan-Xing, Liu Jing-Jing, Yang Xiao-Ning, Jazag Amarsanaa, Ren Jian-Lin and Guleng Bayasi, Fibrinogen Alpha Chain Acts as a HBsAg Binding Protein and their Interaction Promotes HepG2 Cell Apoptosis, Current Proteomics 2014; 11 (1) . https://dx.doi.org/10.2174/1570164611666140412003740
DOI https://dx.doi.org/10.2174/1570164611666140412003740 |
Print ISSN 1570-1646 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6247 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Metabolic Syndrome and Chronic Liver Disease
Current Pharmaceutical Design Development of Meat and Poultry Products Enriched with n-3 PUFAs and their Functional Role
Current Nutrition & Food Science Nutritional Targeting of Cyclooxygenase-2 for Colon Cancer Prevention
Inflammation & Allergy - Drug Targets (Discontinued) The Role of Anti-LeY Antibody in the Downregulation of MAPKs/COX-2 Pathway in Gastric Cancer
Current Drug Targets Cutting through the Complexities of mTOR for the Treatment of Stroke
Current Neurovascular Research Autophagy and Crohns Disease: At the Crossroads of Infection, Inflammation, Immunity, and Cancer
Current Molecular Medicine Anaplastic Lymphoma Kinase as a Therapeutic Target in Anaplastic Large Cell Lymphoma, Non-Small Cell Lung Cancer and Neuroblastoma
Anti-Cancer Agents in Medicinal Chemistry Data Processing and Analytic Support in the PLCO Cancer Screening Trial
Reviews on Recent Clinical Trials Clinico-Pathologic and Biologic Predictors of EGFR Inhibitors Activity and Efficacy in Lung and in Colorectal Cancer
Current Signal Transduction Therapy Targeted Elimination of Leukemia Stem Cells; a New Therapeutic Approach in Hemato-Oncology
Current Drug Targets Selenium-Rich Foods: a Promising Approach to Colorectal Cancer Prevention
Current Pharmaceutical Biotechnology The Clinical Prognostic Value of LRG1 in Esophageal Squamous Cell Carcinoma
Current Cancer Drug Targets The Typical Metabolic Modifiers Conferring Improvement in Cancer Resistance
Current Medicinal Chemistry Lycopene Modulation of Molecular Targets Affected by Smoking Exposure
Current Cancer Drug Targets Targeting the Folate Receptor: Improving Efficacy in Inorganic Medicinal Chemistry
Current Medicinal Chemistry Insight View on Possible Role of Fluoroquinolones in Cancer Therapy
Current Topics in Medicinal Chemistry Pharmacophore, 3D-QSAR Models and Dynamic Simulation of 1,4-Benzothiazines for Colorectal Cancer Treatment
Combinatorial Chemistry & High Throughput Screening New Issues for Copper-64: from Precursor to Innovative Pet Tracers in Clinical Oncology
Current Radiopharmaceuticals Transport Mechanisms at the Blood-Cerebrospinal-Fluid Barrier: Role of Megalin (LRP2)
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) subject Index To Volume 5
Combinatorial Chemistry & High Throughput Screening